sparteine


Also found in: Dictionary, Medical, Wikipedia.

sparteine

[′spärd·ē‚ēn]
(organic chemistry)
C15H26N2 A poisonous, colorless, oily alkaloid; soluble in alcohol and ether, slightly soluble in water; boils at 173°C; used in medicine. Also known as lupinidine.
References in periodicals archive ?
(7) In addition to biochemical evidence, the colocalization of sparteine oxidation deficiency and of the CYP2D6 locus at chromosome 22q13.1 confirmed CYP2D6 as the target gene of the debrisoquine/sparteine polymorphism.
Proceedings: N-oxidation of sparteine in man and its interindividual differences.
Phenotyping investigations in whites have consistently shown that 5% to 10% of the population are poor metabolizers with high metabolic ratios for probe drugs such as debrisoquin, sparteine, and dextromethorphan; in Asians only 0% to 1% of populations display poor metabolizing behavior.
At about the same time, an inborn defect of the metabolism of a drug called debrisoquine was found in England[10] and of the drug sparteine in Germany.[11] Our laboratory,[12] like a Swedish laboratory,[13] compared these 2 defects in some people.
These authors also remind that food flavorings sparteine, allylhexanoate and quinine were banned by these regulators in the early 80 according to the results of studies of acute and long-term toxicity tests carried out in different systems.
Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1991;49:686-93.
In previous studies individuals have been classified as poor, extensive, or ultrarapid CYP2D6 metabolizers according to their metabolic activity exerted on specific test drugs such as debrisoquine or sparteine (28-30).
Previous studies used phenotyping with a variety of probe drugs, e.g., sparteine and debrisoquine (23).
Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 1994;350: 434-9.